Vectura Pharma was established in 1997, and its headquarters are in Chippenham in the U.K. Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases Vectura entered into its first global commercialisation and development agreement with Novartis for NVA237. The company’s marketed products include Ultibro Breezhaler and Seebri Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD).